Document:

EX-10.5

 

CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE

SECURITIES AND EXCHANGE COMMISSION

ASTERISKS DENOTE OMISSIONS

EXHIBIT 10.5

CONSULTING AGREEMENT

     This Consulting Agreement (“Agreement”) is signed on April 28, 2006 and effective as of May 2,
2006 (“Effective Date”) by and between OSI Pharmaceuticals, Inc., a Delaware corporation (together
with its affiliates and subsidiaries, “OSI”), having executive offices at 41 Pinelawn Road,
Melville, New York 11747, and David Guyer (“Consultant”), having an address at **.

1. CONSULTING SERVICES.

     The initial phase of the Term (as defined in Section 13 hereof) shall commence on the
Effective Date and continue until the day immediately prior to the first anniversary of the
Effective Date and shall be referred to herein as the “Transition Phase”. The period commencing
with the first anniversary of the Effective Date and continuing through the remainder of the Term
shall be referred to herein as the “Consulting Period”. Consultant shall provide consulting
services to OSI during the Term as follows:

	 	(a)	 	During the Transition Phase, Consultant shall provide advice and
consultation to, as needed and reasonably requested by, OSI and its subsidiary, (OSI)
Eyetech, Inc. (“(OSI) Eyetech”) regarding the business and operations of (OSI) Eyetech
so as to facilitate an orderly transition of the duties and responsibilities undertaken
by Consultant prior to the Effective Date in his role as head of the (OSI) Eyetech
business to his successor in such role. Consultant will be available to provide such
Services not less than ** days per month for this purpose during the
Transition Phase.

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

 

 

	 	(b)	 	During the Transition Phase and during the Consulting Period, Consultant
will provide advice and consultation to, as needed and reasonably requested by, the
Board of Directors of OSI and the CEO and other members of senior management of OSI
relating to the field of ophthalmology. In addition, during the Term, Consultant will
serve as a technical advisor to the eye disease subcommittee of the OSI Board of
Directors. Consultant will be available to provide such Services not less ** days per month during the Term.
	 
	 	(c)	 	The services described in subsection (a) and subsection (b) above shall be collectively referred to herein as the “Services.”

2. DELIVERY OF CONSULTING SERVICES.

     Consultant will carry out the Services to the best of Consultant’s ability in a professional
manner consistent with industry standards, in accordance with the standard of care customarily
observed with regard to such services in Consultant’s profession and using the Consultant’s
expertise and creative talents. Consultant will perform the Services in a timely manner and at a
location, time and place that Consultant deems appropriate. Consultant will perform the Services
in compliance with all applicable laws, rules and regulations.

3. COMPENSATION AND REIMBURSEMENT.

	 	(a)	 	During the Transition Phase, OSI shall pay Consultant an annual retainer of
$775,000 which shall be due and payable in two equal installments on November 2, 2006
and May 2, 2007. During the Consulting Period, OSI shall pay Consultant an annual
retainer of $250,000 which shall be due and payable in two

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

2

 

	 	 	 	equal installments on the anniversaries of the payment dates during the Transition Phase.
	 
	 	(b)	 	OSI will reimburse Consultant for reasonable out-of-pocket expenses incurred
in connection with the Consultant’s performance of the Services upon the presentation
of receipts for such expenses. To the extent feasible, Consultant will use
OSI-designated travel services to make all OSI requested travel arrangements.

4. USE OF OFFICE AND SUPPORT STAFF.

     During the Term, OSI shall provide to Consultant the use of an office at OSI’s Times Square
facility or another OSI facility mutually agreed upon by Consultant and OSI; provided, however,
that the foregoing shall in no way obligate OSI to maintain a facility in New York City for the
duration of the Term. During the Term, OSI shall also provide to Consultant administrative support
services mutually agreed upon by OSI and Consultant.

5. CONFIDENTIALITY.

	 	(a)	 	“Confidential Information” means confidential or proprietary information of
OSI either disclosed orally, graphically, in writing, or in electronic or other form to
or otherwise learned by Consultant during the course of his employment by OSI and (OSI)
Eyetech and under this Agreement or that should reasonably be known by Consultant to be
confidential or proprietary to OSI, including but not limited to information relating
to OSI’s research, development, preclinical and clinical programs, data and results;
product candidates and products; inventions, works of authorship, trade secrets,
processes, conceptions, formulas, patents, patent applications and licenses; IP Rights
(as defined in Section 8); business, product, marketing, sales, scientific and
technical strategies, programs and results, 

3

 

	 	 	 	including costs and prices; suppliers,
manufacturers, customers, market data, personnel, and consultants; and other
confidential matters related to OSI, but not including Consultant’s general knowledge
and know how.

	 	(b)	 	Subject to Section 5(c), until ** years after the
expiration or termination of this Agreement, Consultant:

	 	(i)	 	shall not use Confidential Information for his own benefit or the
benefit of any third party except solely for the purpose of performing
Services;
	 
	 	(ii)	 	shall hold Confidential Information in strictest confidence and
shall not disclose Confidential Information to others;
	 
	 	(iii)	 	shall use reasonable efforts to protect the confidentiality of
Confidential Information; and
	 
	 	(iv)	 	shall notify OSI as promptly as practicable of discovery of any
unauthorized use or disclosure of Confidential Information.

	 	(c)	 	Consultant’s obligations under Section 5(b) shall not apply to any
Confidential Information that:

	 	(i)	 	is now, or becomes in the future, publicly available other than by
an act or omission of Consultant in violation of this Section 5;
	 
	 	(ii)	 	a third party discloses to Consultant, without any legal
restriction on disclosure known to Consultant, and without any breach of any direct or indirect obligation of confidentiality to OSI
known to Consultant; or

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

4

 

	 	(iii)	 	was or is independently developed by Consultant or others on
Consultant’s behalf without using any Confidential Information or violating any
of Consultant’s obligations under this Agreement.

	 	(d)	 	Notwithstanding other provisions of this Agreement, Consultant may disclose
Confidential Information to the extent and to the persons or entities required under
applicable governmental law, rule, regulation or order, provided that Consultant (i)
first gives prompt notice of such disclosure requirement to OSI so as to enable OSI to
seek any limitations on or exemptions from such disclosure requirement and (ii)
reasonably cooperates at OSI’s request in any such efforts by OSI, at OSI’s
expense.
	 
	 	(e)	 	Upon the earlier of the completion of the Services or OSI’s request for any
reason at any time, Consultant will (i) immediately cease all commercial use of
Confidential Information and notify OSI and (ii) promptly, at OSI’s instruction, either
return to OSI or destroy all Confidential Information that exists in tangible form,
including destroying (but not returning to OSI) any copies, extracts, summaries, or
derivative works thereof, and certify in writing to OSI the completion of such return
and/or destruction.
	 
	 	(f)	 	OSI retains all right, title and interest in and to Confidential
Information. This Agreement gives Consultant no right or license to any Confidential
Information or any intellectual property or other rights owned by or licensed to OSI,
by implication or otherwise, except the right to use Confidential Information solely
for performance of Services. OSI may freely transfer, disclose and/or use Confidential
Information for its or others’ purposes.

5

 

6. CERTAIN AGREEMENTS.

	 	(a)	 	During the Term, Consultant shall not serve as an employee of, or consultant
to, or owner of more than ** of the equity of, any company that is a
Competing Business at the time Consultant serves in such capacity. For purposes of
this Agreement, “Competing Business” means (i) during the period beginning on the
Effective Date and ending on the first anniversary of the Effective Date, any company
that ** of **, (ii) during the period beginning on the first anniversary of the
Effective Date and ending on the second anniversary of the Effective Date, any
company that ** and (iii) at any time during the Term, any company that **. For the
avoidance of doubt, **.
	 
	 	(b)	 	During the Term, Consultant shall not, individually or on behalf of or
through any third party, directly or indirectly, (i) solicit, entice or persuade or
attempt to solicit, entice or persuade any employees of or consultants to OSI to leave
the service of OSI for any reason, or employ, cause to be employed, or solicit the
employment of, any employees of or consultants to OSI while any such person is
providing services to OSI, or (ii) solicit, divert or appropriate or attempt to
solicit, divert or appropriate, any customers of OSI’s Eye Business for the purpose of
directly competing with OSI’s Eye Business. For purposes of this Section 6, “Eye
Business” shall specifically refer to **.

7. INJUNCTIVE RELIEF.

     Consultant expressly acknowledges that any breach or threatened breach of any of the terms
and/or conditions set forth in Sections 5 and 6 of this Agreement will result in substantial,

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

6

 

continuing and irreparable injury to OSI. Therefore, in addition to any other remedy that may be
available to OSI, OSI will be entitled to injunctive or other equitable relief by a court of
appropriate jurisdiction in the event of any breach or threatened breach of the terms of Sections 5
and 6 of this Agreement.

8. INTELLECTUAL PROPERTY.

     Consultant hereby assigns to OSI all of Consultant’s right, title and interest in and to any
intellectual property rights arising from inventions, software programs, databases or other
discoveries made, conceived, reduced to practice, authored or otherwise developed solely or jointly
by Consultant or any of Consultant’s employees or agents in whole or in part through use of
Confidential Information or in the course of performing Services (“IP Rights”). Consultant hereby
grants OSI an irrevocable power of attorney to execute on Consultant’s behalf patent and copyright
applications or other such documents required to protect, enforce or perfect OSI’s right, title and
interest in and to such IP Rights.

9. PUBLICATION.

     Consultant agrees that, during the term of this Agreement and for a period of **
years from termination of this Agreement, if for any reason Consultant wishes to present or publish
scientific articles or papers concerning Consultant’s own research work, the content of which is
based on Confidential Information first received from OSI, Consultant shall submit such proposed presentations, articles and papers to
OSI for its review and possible action to protect OSI’s patent rights at least ** days prior to the
publication or disclosure date. OSI will promptly review Consultant’s proposed presentations or
publications.**

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

7

 

10. REPRESENTATION AND WARRANTIES.

     Consultant represents and warrants to OSI that:

	 	(a)	 	Consultant has the full right, power and authority to enter into this
Agreement and perform its obligations hereunder without the consent of any third party
and without breach of any agreements with or obligations to any third party;
	 
	 	(b)	 	Consultant will not grant, transfer, assign or convey, directly or
indirectly, any right, title or interest in or to any IP Rights to any third party;
	 
	 	(c)	 	Consultant has not entered and will not enter into any agreement with or
obligation to a third party inconsistent, incompatible, or conflicting with its
obligations under this Agreement; and
	 
	 	(d)	 	Consultant will inform OSI immediately of any contracts or subject matter
with which Consultant or members of Consultant’s family are engaged in that may in any
way raise a conflict of interest between Consultant and OSI.

11. INDEMNIFICATION.

     Each party will defend, indemnify and hold harmless the other party, its officers, directors,
employees and agents from and against any and all losses, liabilities, damages, expenses and costs
(including reasonable attorney’s fees) (“Losses”) directly caused by or resulting from a material
breach of this Agreement by such party, except to the extent such Loss was caused by the gross
negligence or willful misconduct of the party (including its officers, directors, employees and
agents) seeking indemnification. Each party will notify the other party promptly upon learning of
a claim, demand, suit, or proceeding of which it is aware that would reasonably be expected to give
rise to a Loss, and the potentially indemnifying party may control defense and settlement thereof
provided it does so diligently, in good faith and using reasonably

8

 

experienced counsel with
expertise in the relevant field. The potentially indemnified party will reasonably cooperate in
such defense and/or settlement at the potentially indemnifying party’s request and expense and may
participate at its own expense using its own counsel.

12. WAIVER AND RELEASE.

     Except with respect to compensation set forth in Section 3, Consultant hereby waives, fully
releases and forever discharges OSI and its agents, employees, successors and assigns from and
against any and all demands, claims, actions, causes of action, rights, suits, covenants, contracts
and agreements of any kind, known or unknown, absolute or contingent, determined or speculative,
both in law and in equity, brought or made by or on behalf of Consultant, arising out of
Consultant’s services under and pursuant to the Agreement.

13. TERM AND TERMINATION.

	 	(a)	 	The term of this Agreement shall commence on the Effective Date and expire
on the fourth anniversary of the Effective Date (the “Term”) unless earlier terminated
under this Section 13.
	 
	 	(b)	 	Either party may terminate this Agreement for a material breach by the other
party upon ** days’ written notice specifying the breach unless such
breach is cured within such ** day period.
	 
	 	(c)	 	The Consultant may terminate this Agreement at any time and for any reason
upon ** days’ written notice to OSI.
	 
	 	(d)	 	Expiration or termination of this Agreement shall not affect accrued rights
or obligations of the parties. Sections 5, 7, 8, 9, 10(c), 10(d), 10(e), 11, 12, 13(d),
15, 16, 17 and 18 shall survive termination or expiration of this Agreement.

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

9

 

14. CHANGE OF CONTROL.

     Upon a “Change of Control” of OSI, all amounts remaining to be paid to Consultant under this
Agreement shall become immediately due and payable and this Agreement shall terminate. “Change of
Control shall be defined as ** .

15. STOCK OPTIONS.

     The Consultant’s stock options to acquire common stock of OSI shall not terminate as a result
of the termination of Consultant’s employment with OSI and commencement of this consulting
arrangement, but instead shall continue to vest during the Term on the same terms as they would
have vested if Consultant had remained employed by OSI during such time period.

16. ACKNOWLEDGEMENT.

     OSI acknowledges that Consultant intends to commence immediately a relationship, which may be
as a partner, consultant, advisor, employee, or in some other capacity, with SV Life Sciences.
Without limiting the generality of the foregoing, OSI acknowledges that Consultant may, during the
Term, (i) serve as an employee or partner of, or consultant to, any venture capital firm or other
institutional investor, (ii) assist in the evaluation of investment opportunities by any venture
capital firm or other institutional investor, and (iii) serve on the board of directors of, or as
an employee of or consultant to, any company that is not a Competing Business. In particular, the
Consultant has advised OSI that he may, and OSI acknowledges that Consultant may, join the board of
directors of each of Optos plc, a retinal imaging company, and NeoVista, Inc., a company developing
a radiation probe device for macular degeneration.

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

10

 

17. INDEMNITY.

     From the Effective Date through the sixth anniversary of the last day of the Term, OSI and
(OSI) Eyetech shall jointly and severally indemnify the Consultant, and hold the Consultant
harmless against, all claims, losses, liabilities, damages, judgments, fines and reasonable fees,
costs and expenses, including attorneys’ fees and disbursements, incurred in connection with any
claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or
investigative, arising out of or by reason of the fact that the Consultant is or was an officer,
director, employee or agent of OSI or any of its subsidiaries, to the fullest extent permitted
under Delaware law. OSI shall pay all expenses, including reasonable attorneys’ fees, that may be
incurred by the Consultant in connection with his enforcement of his rights provided in this
Section 17. The provisions of this Section 17 are intended to be in addition to the rights
otherwise available to the Consultant by law, charter, bylaw or agreement, and shall operate for
the benefit of, and shall be enforceable by, the Consultant and his heirs and representatives.

18. GENERAL.

	 	(a)	 	This Agreement shall be interpreted and enforced in accordance with the laws
of the State of New York, regardless of any choice of law principles that would cause
the application of the law of any other jurisdiction. The parties will submit any
dispute or claim arising under this Agreement to the exclusive jurisdiction of the U.S.
federal or New York state courts within the counties of New York or Suffolk, and the
parties hereby submit to, and waive any objection to, personal jurisdiction and venue
in such courts for such purpose.
	 
	 	(b)	 	Any purported assignment or delegation by Consultant of this Agreement in
whole or in part without the prior written consent of OSI
shall be void. OSI has 

11

 

	 	 	 	the unconditional right to assign this Agreement if
there is no resulting material change in the scope of the Services. This Agreement
shall be binding upon the parties, their successors and their permitted assigns.

	 	(c)	 	All notices under this Agreement shall be in writing and shall be deemed
given upon personal delivery, delivery by internationally- or nationally-recognized
bonded courier service, or seven days after sending by certified or registered mail,
postage prepaid and return receipt requested, to the following addresses of the
respective parties or such other address as given by notice under this Section
18(c):

	 	 	 
	OSI:

	 	OSI Pharmaceuticals, Inc.
	 

	 	At the address set forth at the beginning of this Agreement
	 

	 	Attention: General Counsel
	 
	 	 
	Consultant:

	 	David Guyer
	 

	 	At the address set forth at the beginning of this Agreement

	 	(d)	 	During the Term, Consultant agrees to abide by the terms of OSI’s
insider trading policy attached hereto as Exhibit A; provided, however, that Consultant
may enter into a trading plan compliant with Rule 10b5-1 under the Securities Exchange
Act of 1934 providing for a sale by Consultant of securities of OSI at times that would
otherwise be prohibited by OSI’s insider trading policy.
	 
	 	(e)	 	During the term of this Agreement, Consultant will not improperly use or
disclose to OSI any proprietary information or trade secrets of any former or
concurrent employer or other person or entity.
	 
	 	(f)	 	Consultant recognizes that OSI has received and in the future will receive
from third parties their confidential or proprietary information subject to a duty on
OSI’s part to maintain the confidentiality of such information and to use it only 

12

 

	 	 	 	for certain limited purposes. Consultant agrees to hold all such confidential or
proprietary information in the strictest confidence and not to disclose it to any
person, firm or corporation or to use it except as necessary in carrying out
Consultant’s work for OSI consistent with the OSI’s agreement with such third
party.

	 	(g)	 	This Agreement sets forth the complete, final and exclusive agreement
between the parties and supersedes and terminates all prior written and oral agreements
and understandings between Consultant, on the one hand, and OSI and its subsidiaries,
including (OSI) Eyetech, on the other hand, other than the stock option agreements
between OSI and Consultant. No amendment to, or waiver of right under, this Agreement is
effective unless in writing signed by authorized representatives of the parties. No
waiver by a party of any breach of this Agreement shall be a waiver of any preceding
or succeeding breach. No waiver by a party of any right under this Agreement shall
be construed as a waiver of any other right. If any provision of this Agreement is
judicially or administratively determined to be unenforceable, the provision will be
reformed to most nearly approximate the parties’ original intent, but otherwise this
Agreement will continue in full force and effect.
	 
	 	(h)	 	Consultant’s relationship with OSI will be that of an independent
contractor, and nothing in this Agreement shall be construed to create a partnership,
joint venture, or employer-employee relationship. Consultant is not the agent of OSI
and is not authorized to make any representation, contract, or commitment on behalf of
OSI. Consultant will be solely responsible for all tax returns and payments required
to

13

 

	 	 	 	be filed with or made to any federal, state or local tax authority with respect to
Consultant’s performance of services and receipt of fees under this Agreement.
Consultant will not be entitled to any of the benefits that OSI may make available to
OSI employees, such as group insurance, profit-sharing or retirement benefits. OSI
will regularly report amounts paid to Consultant by filing Form 1099-MISC with the
Internal Revenue Service as required by law, and OSI will not withhold or make payments
for social security, make unemployment insurance or disability insurance contributions,
or obtain worker’s compensation insurance on Consultant’s behalf. Consultant accepts
exclusive liability for complying with all applicable state and federal laws governing
self-employed individuals, including obligations such as payment of taxes, social
security, disability and other contributions based on fees paid to Consultant, its
agents or employees under this Agreement, and will defend, indemnify and hold harmless
OSI from and against any and all such taxes or contributions, including penalties and
interest.

	 	(i)	 	This Agreement may be executed simultaneously in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

14

 

     The parties hereto have entered into this Agreement as of the Effective Date by their duly
authorized representatives.

	 	 	 	 	 	 	 
	/s/	 	 	 	OSI PHARMACEUTICALS, INC.
	 

David Guyer

	 	 	 	 	 	 
	(Consultant)
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Social Security Number

	 	 	 	By:
	 	/s/
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	**
	 	 	 	 	 	 
	 

	 	 	 	 	 	 

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.

[Signature page to consulting agreement]

 

 

Exhibit A**

 

			
	**	 	This portion has been redacted pursuant to a confidential treatment request.EX-10.6

 

EXHIBIT 10.6

Compensatory Arrangements for Executive Officers

     The Compensation Committee (the “Committee”) of the Board of Directors of OSI Pharmaceuticals,
Inc. (“OSI” or the “Company”) approved the 2007 salaries and 2006 cash bonuses for OSI’s principal
executive officer, principal accounting officer and other named executive officers (as that term is
defined in Item 402 of Regulation S-K) as set forth in OSI’s proxy statement dated May 4, 2007 (the
“2007 Proxy”), excluding David R. Guyer, M.D., who resigned from the Company in May 2006. The
following table sets forth the annual base salary level of such officers for 2007 and the 2006 cash
bonuses for each such officer:

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	Name and Position	 	 	2007 Base Salary	 	 	2006 Bonus	 
	 	Colin Goddard, Ph.D.

Chief Executive Officer(1)
	 	 	$	600,000	 	 	 	 	—	 	 
	 	Michael G. Atieh

Executive Vice President, Chief Financial Officer
and Treasurer
	 	 	$	425,000	 	 	 	$	205,000	 	 
	 	Gabriel Leung

Executive Vice President and President,
(OSI) Oncology
	 	 	$	420,000	 	 	 	$	204,000	 	 
	 	Anker Lundemose, M.D., Ph.D., D.Sc.

Executive Vice President and President,
(OSI) Prosidion
	 	 	$	402,250	 	 	 	$	196,220	 	 
	 	Paul Chaney

Executive Vice President and President, (OSI)
Eyetech
	 	 	$	378,500	 	 	 	$	182,000	 	 
	 

			
	(1)	 	Given the market performance of Macugen® (pegaptanib sodium injection), and the resulting
decision of OSI to exit the eye disease business it acquired through it acquisition of Eyetech
Pharmaceuticals, Inc. in November 2005, the Committee concurred with Dr. Goddard’s
recommendation that he not receive a 2006 bonus or merit increase to his 2007 base salary.

Cash Bonuses

     The 2006 bonus awards were computed in accordance with the Committee’s policy awarding annual
bonuses for executive officers, as disclosed in the Compensation Discussion and Analysis section of
the 2007 Proxy, and are consistent with past practices. OSI has established a discretionary annual
cash bonus program for all of its employees, including its executive officers. The bonus targets,
which are a percentage of base salary, for all of its executive officers are based upon their
respective grade levels. The amount of bonus actually paid to its employees, including the
executive officers (other than OSI’s CEO), is a function of the corporate and individual
performance measures. The CEO’s bonus is based entirely on corporate performance measures.
Consistent with its compensation objectives, a larger portion of the bonuses for OSI’s executive
officers is tied to corporate performance as compared to individual performance. In addition, the
performance of their respective department(s) or function group(s) is the largest component in
measuring the individual performance for executive officers (other than the CEO).

 

 

     The actual amount of the bonuses paid to its executive officers, including the CEO, varies
depending upon the Company’s performance and, for executive officers other than the CEO, such
executive officers’ individual performance. The corporate component has historically ranged between
80% and 150% of the corporate component target and the individual performance component ranges
between 90% and 120% of the individual performance component target depending upon an executive’s
individual performance rating. In 2006, the Committee set the corporate component at 100%. The
individual component of the annual cash bonus is based on the executive officer’s individual
performance rating, determined in the manner discussed above. For 2006, the individual performance
component of the annual cash bonus was set at 100% for executive officers who received one of the
top three performance ratings. In 2006, each of the executive officers received one of the top
three performance ratings, resulting in an individual performance component of 100% for each them.

     The bonus targets for the named executive officers are either set in accordance with their
employment agreements or are based upon their respective grade levels. The 2007 bonus targets
(which represents a percentage of base salary) for the named executive officers are as follows:

	 	 	 	 	 
	Name	 	Target	 
	Colin Goddard, Ph.D.
	 	 	*	 
	Michael G. Atieh
	 	 	50	%
	Gabriel Leung
	 	 	50	%
	Paul G. Chaney
	 	 	50	%
	Anker Lundemose, M.D., Ph.D., D.Sc.
	 	 	50	%

			
	 	 	 

* No specific target. Determined by the Committee in its discretion.

Equity Awards

     OSI grants equity awards of stock options, restricted stock and restricted stock units to its
employees under its Amended and Restated Stock Incentive Plan. Most of its employees, including
its executive officers, receive an annual equity grant in December. The total amount of equity to
be granted is initially determined by the CEO in consultation with the Vice President of Human
Resources, and then recommended to the Committee for approval. The exercise price for all stock
options is set at the closing price of OSI’s common stock on the date that the Committee approves
the annual grant, with such approval date serving as the date of grant. Equity grants to the named
executive officers are formula based and designed to provide a level of equity compensation that is
at the approximate 50th percentile of that awarded by OSI’s peer group of companies. OSI determines
the value of the grants provided to each executive officer by assigning such executive officer with
a fixed grant percentage based on his or her grade level and then multiplying this percentage by
his or her annual salary. For 2006, the named executive officers received either 100% or 75% of
their formula grant, based on their individual performance ratings.

Perquisites

-2-

 

     OSI provides very few perquisites to its executive officers. Certain of its named executive
officers receive a leased car or car allowance, reimbursement of relocation expenses,
legal fees and home security systems.

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]